Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Докторантска мрежа2016–2021

BioCapture · Smart capture phases for proteomics, glycomics and biomarker assays

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2016-11-01 → 2021-10-31
Финансиране от ЕС
2 982 872 €
Участници
14
Схема
MSCA-ITN-ETN

Линиите свързват координатора с партньорите.

Накратко на български

Специални полимери и „пластмасови антитела“ се разработват за улавяне на специфични маркери, като например тези при рак на белия дроб. Тези инструменти помагат за по-ранно и точно откриване на заболяванията чрез анализ на протеини и захари в организма.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Smart capture phases for proteomics, glycomics and biomarker assays

Cancer medicine experiences currently a strong need for sensitive, robust and affordable diagnostic tools that can sense cellular states early during disease progression. In BioCapture we have addressed this need while harnessing novel molecular capture technology targeting tumor specific markers. Molecularly imprinted polymers (MIPs) and “plastic antibodies” and other smart materials have been developed and used to detect previously inaccessible tumor markers and to discover novel disease biomarkers. The project engaged 11 ESRs full time within a time frame of four years. The research performed was highly interdisciplinary comprising molecular imprinting, materials chemistry, optical sensor technology, proteomics and diagnostics. The objectives of Bioacapture were to: • prepare 11 young researchers for a succesfull career in industry and academia. • develop proteomics capture phases for unstable post-translational modifications (PTMs) and PTM peptide sequence motifs. • develop imprinted capture phases for lung cancer biomarkers • develop saccharide specific capture phases. • develop addressable fluorescent MIPs. • develop high throughput multiplex assays. • validate the novel diagnostic tools using clinical samples • establish long lasting collaborations among polymer/materials, proteomics and clinical researchers. Main conclusions: We have progressed beyond expectation towards our goals to develop affinity based tools and reagents. Robust peptide- and PTM- specific capture materials compatible with proteomics work flows and MS have been used to develop assays with a potential diagnostic value. We have also advanced well on a fundamental materials, analytical and cell biology science level. A detailed macroscopic and molecular level characterisation of the imprinted receptors have increased our understanding of the nature of the binding sites and how they are formed. Finally, genetically engineered cell libraries has provided a perfect model system for imitating cancer cells and for probing receptor binding affinity and specificity.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

The overall objective of BioCapture is to develop novel robust assays for proteinaceous biomarkers associated with cancerand to develop innovative tools for assaying elusive cancer related posttranslational modifications in proteins. This will beachieved by exploiting robust glycan, peptide and protein binders in the form of Molecularly Imprinted Polymers (MIPs) or plastic antibodies alongside generic enrichment combined with selected reaction monitoring-based mass spectrometry assays. In addition, sequence specific MIPs for multiple proteotypic peptides will be developed for use as capture phases in array format followed by MS or fluorescence based readout as well as a coupling of both detection techniques. The artificial receptors will be developed by various Molecular Imprinting techniques. The research results will lead to technological advances having a major impact on 1) health care since it will profit from methods for earlier, more reliable diagnosis of diseases, 2) drug discovery allowing a faster target or biomarker identification; and 3) biochemistry research laboratories in resulting in improved protein fractionation tools for revealing low abundant post translational modifications. The training of researchers will be performed by a consortium consisting of in total 15 partners whereof 6 polymer/materials research groups, 5 protein/glycan chemistry/analysis groups, 1 separation technology companies, 2 expert groups on platforms for multiplex analysis and one diagnostic company. This forms the basis for a very exciting interdisciplinary training program. Thus 11 early stage researchers (ESRs) working on specific tasks within five work packages will follow a rich training program providing a well-balanced spectrum of scientific, business and entrepreneurial skills.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз